(Q34647109)

3 August 2017

title

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma (English)

1 reference

3 August 2017

main subject

phase III clinical trial

0 references

1 reference

Grant A McArthur

16

0 references

Michele Maio

Michele Maio

13

0 references

Richard F. Kefford

Richard Kefford

2

0 references

Paul Lorigan

Paul Lorigan

11

0 references

Antoni Ribas

1

Antoni Ribas

1 reference

3 August 2017

9

Jacob Schachter

1 reference

3 August 2017

24

Axel Hauschild

1 reference

3 August 2017

Margaret A Marshall

3

1 reference

3 August 2017

Cornelis J A Punt

4

1 reference

3 August 2017

John B Haanen

5

1 reference

3 August 2017

Maribel Marmol

6

1 reference

3 August 2017

Claus Garbe

7

1 reference

3 August 2017

Helen Gogas

8

1 reference

3 August 2017

Gerald Linette

10

1 reference

3 August 2017

Kari L Kendra

12

1 reference

3 August 2017

Uwe Trefzer

14

1 reference

3 August 2017

Michael Smylie

15

1 reference

3 August 2017

Brigitte Dreno

17

1 reference

3 August 2017

Paul D Nathan

18

1 reference

3 August 2017

Jacek Mackiewicz

19

1 reference

3 August 2017

John M Kirkwood

20

1 reference

3 August 2017

Jesus Gomez-Navarro

21

1 reference

3 August 2017

Bo Huang

22

1 reference

3 August 2017

Dmitri Pavlov

23

1 reference

3 August 2017

language of work or name

English

0 references

publication date

7 January 2013

1 reference

Journal of Clinical Oncology

3 August 2017

published in

1 reference

3 August 2017

volume

31

1 reference

3 August 2017

issue

5

1 reference

3 August 2017

page(s)

616-622

1 reference

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

3 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4878048

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4878048

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4878048

Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4878048

Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4878048

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4878048

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4878048

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4878048

Phase I/II trial of tremelimumab in patients with metastatic melanoma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4878048

Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4878048

26 October 2018

Identifiers

DOI

10.1200/JCO.2012.44.6112

1 reference

3 August 2017

1 reference

3 August 2017

1 reference